8-K: Regen Biopharma Advances HemaXellerate to Phase I

Regen Biopharma, Inc. is advancing its HemaXellerate therapy into a Phase I clinical trial, compensating key personnel with 40 million newly issued common shares.

Summary

• Regen Biopharma, Inc. entered into a consulting agreement with Dr. Harry Lander on October 2, 2025, to assist with a planned Phase I Clinical Trial of HemaXellerate.
• The company also entered into an agreement with David Koos, Chairman and CEO, on October 2, 2025, for his services related to the same Phase I Clinical Trial.
• Dr. Lander was compensated with 20 million newly issued common shares, and David Koos was compensated with 20 million newly issued common shares.
• All 40 million compensation shares are subject to a vesting schedule, with full vesting upon the successful completion of the planned Phase I Clinical Trial of HemaXellerate.
• HemaXellerate is a stem cell derived therapy, specifically a cellular composition of autologous stromal vascular fraction from adipose tissue, intended for patients with drug-refractory aplastic anemia.
• The Phase I clinical trial aims to determine the safety and potential efficacy of intravenously administered autologous stromal vascular fraction (SVF) cells.
• Primary endpoints for the trial are safety and feasibility, with secondary endpoints assessing efficacy through complete response, partial response, or relapse.
• As of October 3, 2025, Regen Biopharma, Inc. has 79,374,704 common shares outstanding, reflecting the issuance of these 40 million shares.

Sentiment

Score: 5

Explanation: The advancement of a key drug candidate into Phase I clinical trials is a positive step for a biopharma company, indicating progress. However, the significant dilution of over 50% for existing shareholders due to equity compensation for management and a consultant introduces a notable negative impact, balancing the overall sentiment to neutral.

Positives

• Advancing HemaXellerate, a stem cell derived therapy for drug-refractory aplastic anemia, into a Phase I clinical trial.
• Securing the expertise of Dr. Harry Lander to assist with the critical Phase I clinical trial.
• Aligning the compensation of the Chairman and CEO, David Koos, directly with the successful completion of the Phase I clinical trial, incentivizing performance.

Negatives

• Issuance of 40 million new common shares represents significant dilution for existing shareholders, increasing the total shares outstanding to 79,374,704.
• Compensation for key personnel is entirely equity-based, potentially indicating limited cash resources for operational expenses.
• The vesting of compensation shares is contingent solely on the "successful completion" of the Phase I trial, which can be a subjective and lengthy process.

Risks

• Clinical trial risk: The planned Phase I trial for HemaXellerate may not achieve its primary endpoints of safety and feasibility or demonstrate sufficient efficacy, leading to potential failure.
• Shareholder dilution: The issuance of 40 million new common shares significantly dilutes the ownership percentage of existing shareholders.
• Forfeiture risk: Compensation shares are subject to forfeiture if the consulting period terminates before the successful completion of the Phase I trial.
• Regulatory risk: HemaXellerate, as a novel therapy, is subject to stringent regulatory approval processes, and there is no guarantee of future approvals.

Future Outlook

The company intends to initiate a Phase I clinical trial for HemaXellerate to assess the safety and potential efficacy of intravenously administered autologous stromal vascular fraction (SVF) cells in patients with severe, immune suppressive refractory aplastic anemia. The trial's primary endpoints are safety and feasibility, with secondary endpoints focused on efficacy measures such as complete response, partial response, or relapse.

Management Comments

• David Koos, Chairman and Chief Executive Officer, signed the agreements on behalf of the company and as an individual recipient of compensation shares.

Industry Context

This announcement reflects a typical progression for an early-stage biopharmaceutical company, moving a novel therapeutic candidate, HemaXellerate, into human clinical trials. The use of equity compensation for key personnel and consultants is a common practice in the biotech industry, especially for companies with limited cash flow, to conserve capital while incentivizing long-term success tied to drug development milestones. The focus on a Phase I trial for aplastic anemia positions the company in a niche but high-need therapeutic area.

Comparison to Industry Standards

• Equity-based compensation for management and key consultants is a standard practice in early-stage biotechnology companies, often used to align incentives with long-term drug development success and conserve cash.
• The progression of a novel therapy into a Phase I clinical trial is a critical and standard milestone in the drug development lifecycle, comparable to similar stages for companies like CRISPR Therapeutics (CRSP) or Editas Medicine (EDIT) when they first advanced their gene-editing therapies into human trials.
• The significant dilution from issuing 40 million shares (over 50% increase in outstanding shares) is on the higher end for compensation, but not unprecedented for small-cap biotechs where equity is the primary currency for attracting talent and funding development. For example, some smaller biotechs might issue similar percentages for significant capital raises or mergers.

Related Party Transactions

• The company entered into an agreement with David Koos, the Chairman and Chief Executive Officer, for his services in connection with the planned Phase I Clinical Trial of HemaXellerate, compensating him with 20 million newly issued common shares.

Stakeholder Impact

• Shareholders: Experience significant dilution (over 50% increase in shares outstanding) from the issuance of 40 million new common shares, which could negatively impact per-share value. However, successful clinical trial progression could lead to long-term value creation.
• Management/Consultant (David Koos, Dr. Harry Lander): Receive substantial equity compensation, aligning their financial incentives directly with the successful completion of the Phase I clinical trial.
• Patients: Potential future benefit from a new therapeutic option for drug-refractory aplastic anemia if HemaXellerate proves safe and effective.

Next Steps

• Initiate the planned Phase I Clinical Trial of HemaXellerate.
• Conduct the trial to determine the safety and potential efficacy of HemaXellerate in patients with drug-refractory aplastic anemia.

Key Dates

Recommendation

The company is taking a crucial step by advancing HemaXellerate into a Phase I clinical trial, which is a positive for a biopharma firm. This progress could unlock significant long-term value if the trial is successful. However, the immediate and substantial dilution of over 50% of outstanding shares to compensate management and a consultant is a significant concern for existing shareholders. Given the early stage of the clinical trial (Phase I), the outcome remains highly uncertain and carries inherent high risk. The balanced view of potential future upside against immediate dilution and high development risk leads to a "Hold" recommendation, suggesting investors monitor trial progress and future financial strategies closely.

Keywords

Regen Biopharma, HemaXellerate, Phase I Clinical Trial, Aplastic Anemia, Stem Cell Therapy, Equity Compensation, Biotechnology, SEC 8-K, Clinical Development, Share Dilution